Artivion (AORT) Expected to Announce Quarterly Earnings on Monday

Artivion (NYSE:AORT) will likely be releasing its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect Artivion to post earnings of $0.12 per share and revenue of $94.81 million for the quarter. Artivion has set its FY 2025 guidance at EPS.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Stock Down 0.1 %

NYSE AORT opened at $23.82 on Monday. Artivion has a 1 year low of $19.36 and a 1 year high of $32.33. The stock has a market capitalization of $1.02 billion, a PE ratio of -1,191.00 and a beta of 1.65. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The business’s 50-day moving average is $24.39 and its 200 day moving average is $27.30.

Insider Activity

In other Artivion news, insider John E. Davis sold 15,100 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the sale, the insider now directly owns 208,778 shares in the company, valued at approximately $4,929,248.58. This trade represents a 6.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 42,156 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the completion of the transaction, the chief executive officer now owns 663,882 shares in the company, valued at approximately $18,130,617.42. This represents a 5.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,799 shares of company stock worth $2,356,223. Corporate insiders own 8.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on AORT shares. Needham & Company LLC reduced their target price on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Stifel Nicolaus dropped their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.